Weightlessness Associated Cephalad Fluid Shifts; The Potential to Evaluate Venous and Lymphatic Dysfunction (NIID)

May 3, 2024 updated by: Heather Barnhart, Nova Southeastern University

The Use of Non-Invasive Imaging Devices (NIID) to Detect Temperature Differentiation and Lymphatic/Venous Flow to the Head and Neck During Head Down Tilt Position Before and After Manual Lymphatic Drainage: The NIID Study

In the weightlessness of space and significant alterations of terrestrial 1 g (1 gravity equivalent) head-to-foot hydrostatic pressure gradients, astronauts experience a dramatic fluid redistribution of ~ 2 liters from the legs to the head and neck within the first 24-48 hours of flight, among other cardiovascular and physiologic system adaptations. After only 4 days in the weightlessness of low earth orbit (LEO), changes can be seen in baroreceptor responsiveness, causing orthostatic hypotension upon subsequent return to Earth. Fluid shifts may also result in headaches, congestion or facial puffiness that can contribute to deteriorating sleep patterns. The ability to manage, mitigate, or offset these fluid shifts is vital to maintain nominal health for short and long duration space flight and potentially improve readaptation to terrestrial gravity or other surface gravity fields, such as the moon or Mars. Fluid shifts towards the cephalic region during microgravity have been speculated to contribute towards spaceflight associated neuro-ocular syndrome (SANS). SANS is a distinct, microgravity-induced phenomenon of neuro-ophthalmic findings observed in astronauts following long-duration spaceflight including choroidal folds, optic disc edema, posterior globe flattening, refractive shift, and cerebral fluid shifts noted to be persistent at 6-month post-flight MRI scans. Thus, noninvasive approaches to studying real-time fluid shifts in weightlessness could serve as critical areas of research to further SANS study and effective countermeasure protocol development. For continuous fluid shift monitoring and management, the goal is to establish baseline assessments utilizing real-time point- of-care noninvasive imaging devices (NIID).

Manual lymphatic drainage (MLD) therapy reduces lymphatic fluid in the affected limb, head, and neck to improve function and prevent progression of fluid build-up. MLD is a therapeutic massage that delivers light pressure through the skin to stimulate lymphatic vessel function. Randomized controlled trials have demonstrated statistically significant improvements in lymphatic function and pain following MLD.

The main objectives of this pilot, retrospective study were to use NIID to examine temperature differential alterations, superficial venous flow patterns (head, neck, upper torso), and venous flow patterns along the lymphatic ventromedial bundles of the medial calves and thighs when in the 6-degree head down tilt (HDT) validated space analogue position and to analyze the effect of MLD therapy administered in the HDT position on lymphatic flow and temperature. HDT is the best validated space analogue currently available for evaluation of fluid redistribution in a timely manner.

Study Overview

Detailed Description

Under the influence of standard developmental physiology on the Earth's surface (1 g), 70% of body fluids reside below the level of the heart. The lymphatic system has the capacity and capability to transport fluid from distal to proximal in an upward manner, against gravity and tissue pressure gradients, via lymphangion contractility, leg muscle contraction, respiratory and chest wall function, thus augmenting a "suction effect" for pumping lymphatic fluid within the subatmospheric pressure tissue distribution zones (the Guyton principle). Lymphatic drainage of the head and neck must be assisted by gravity, since these regions are above the level of the heart. In the weightlessness of space and significant alterations of terrestrial 1 g head-to-foot hydrostatic pressure gradients, astronauts experience a dramatic fluid redistribution of ~ 2 liters from the legs to the head and neck within the first 24-48 hours of flight, among other cardiovascular and physiologic system adaptations. After only 4 days in the weightlessness of LEO, changes can be seen in baroreceptor responsiveness, causing orthostatic hypotension upon subsequent return to Earth. Fluid shifts may also result in headaches, congestion, or facial puffiness that can contribute to deteriorating sleep patterns. The ability to manage, mitigate, or offset these fluid shifts is vital to maintain nominal health for short and long duration space flight and potentially improve readaptation to terrestrial gravity or other surface gravity fields, such as the moon or Mars. Fluid shifts towards the cephalic region during microgravity have been speculated to contribute towards spaceflight associated neuro-ocular syndrome (SANS). SANS is a distinct, microgravity-induced phenomenon of neuro-ophthalmic findings observed in astronauts following long-duration spaceflight including choroidal folds, optic disc edema, posterior globe flattening, refractive shift, and cerebral fluid shifts noted to be persistent at 6-month post-flight MRI scans. Thus, noninvasive approaches to studying real-time fluid shifts in weightlessness could serve as critical areas of research to further SANS study and effective countermeasure protocol development. For continuous fluid shift monitoring and management, the goal is to establish baseline assessments utilizing real-time point-of-care NIID.

MLD therapy reduces lymphatic fluid in the affected limb, head, and neck to improve function and prevent progression of fluid build-up. MLD is a therapeutic massage that delivers light pressure through the skin to stimulate lymphatic vessel function. Randomized controlled trials have demonstrated statistically significant improvements in lymphatic function and pain following MLD.

The main objectives of this pilot, retrospective case series were to use 4 standard-of-care NIIDs to examine temperature differential alterations, superficial venous flow patterns (head, neck, upper torso), and venous flow patterns along the lymphatic ventromedial bundles of the medial calves and thighs when in the 6-degree HDT space analogue position and to analyze the effect of MLD therapy administered in the HDT position on lymphatic flow and temperature. We hypothesize that dermal venous and lymphatic flow patterns of the head, neck, upper torso, and ventromedial bundle flow patterns shifted to cephalad (dermal interstitial fluid increase) and were reversed following MLD therapy in the 6-degree HDT position. More specifically, MLD therapy could alter lymphatic contractility flow patterns and interstitial fluid, in addition to temperature differentials, in the 6-degree HDT position.

The following imaging devices were used to measure fluid redistribution and temperature in the HDT: near-infrared spectroscopy imaging device (SnapShotNIR, Kent Imaging, Calgary, Canada) to capture perfusion changes through and superficial oxygenation saturation measurements; long-wave infrared and wound imaging device (WoundVision Scout, WoundVision, Indianapolis, IN) to capture thermal images measuring physiological temperature differentiation; Lymphatic fluid scanning device (LymphScanner, Delfin Technologies, Miami, FL, USA) to measure percentage water content [tissue dielectric constant (TDC)] consistent with lymphatic flow patterns and interstitial fluid alterations related to positioning.

Study Type

Observational

Enrollment (Actual)

15

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Florida
      • Fort Lauderdale, Florida, United States, 33328
        • Nova Southeastern University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Healthy students between the ages of 18 and 45.

Description

Inclusion Criteria:

  • Students at Nova Southeastern University
  • Aged 18-45 years
  • Body Mass Index ranging from 18.5 to 24.9
  • No known lymphatic dysfunction
  • Written informed consent

Exclusion Criteria:

  • On blood pressure medications
  • On vasodilation medications
  • Uses any form of nicotine

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Healthy students of the Health Professions Division of NSU
Participants arrived at a predesignated room and acclimated to the ambient temperature for 15 minutes. Baseline heart rate, blood pressure, respiration rate, and oxygen saturation were taken and monitored throughout the data collection process. Participants were assessed in the HDT position (validated simulated weightlessness) for 3 hours and 45 minutes. Baseline image assessments were taken 1 minute after assuming the HDT position. Subsequent image assessments were taken every 30 minutes thereafter. Each image acquisition requires ~20 seconds and was performed by 1 of 4 trained imagers. Participants received 15 minutes of an established MLD protocol to the head, neck, and thorax before moving out of position. Immediately post-MLD, reassessment with the devices occurred. A follow-up reassessment was taken with the devices 30 minutes after MLD in the sitting position to assess potential changes and resolution of any symptoms experienced following a return to gravity environment.
MLD is a gentle manual technique used to decongest swollen areas and redirect lymphatic flow to non-congested areas
Oxygen saturation measurement
Other Names:
  • Kent Snapshot
Thermal imaging
Other Names:
  • Long wave infrared
  • Wound Vision Scout
TDC captured by lymphatic fluid scanning device
Other Names:
  • TDC
  • Delfin Lymphscanner

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percent change (%) in TDC level from baseline
Time Frame: Baseline, post-30 minutes, post-60 minutes, post-90 minutes, post-120 minutes, post-150 minutes, post-180 minutes, post-195 minutes (post-MLD), and post-225 minutes (30-minutes-post-MLD)
TDC is a measurement of local tissue water content. The lymphatic fluid scanner will assess TDC levels at the timepoints listed below. The outcome measure is the percent change in these levels to assess change in interstitial fluid in simulated microgravity; the unit is percentage.
Baseline, post-30 minutes, post-60 minutes, post-90 minutes, post-120 minutes, post-150 minutes, post-180 minutes, post-195 minutes (post-MLD), and post-225 minutes (30-minutes-post-MLD)
Percent change (%) in tissue oxygenation saturation level from baseline
Time Frame: Baseline, post-30 minutes, post-60 minutes, post-90 minutes, post-120 minutes, post-150 minutes, post-180 minutes, post-195 minutes (post-MLD), and post-225 minutes (30-minutes-post-MLD).
Tissue oxygenation saturation is an indicator of perfusion changes. NIRS will assess tissue oxygenation at the timepoints listed below. The outcome measure is the percent change in these levels to assess perfusion changes in simulated microgravity; the unit is percentage.
Baseline, post-30 minutes, post-60 minutes, post-90 minutes, post-120 minutes, post-150 minutes, post-180 minutes, post-195 minutes (post-MLD), and post-225 minutes (30-minutes-post-MLD).
Percent change (%) in tissue temperature gradient from baseline
Time Frame: Baseline,post-30 minutes, post-60 minutes, post-90 minutes, post-120 minutes, post-150 minutes, post-180 minutes, post-195 minutes (post-MLD), and post-225 minutes (30-minutes-post-MLD).
Tissue temperature gradient measures the change in temperature at an area of interest compared to surrounding tissues. Fluid shifts are associated with tissue temperature alterations. LWIT will assess the tissue temperature gradient at the timepoints listed below. The outcome measure is the percent change in temperature gradients to assess changes in thermal energy at an area of interest in simulated microgravity; the unit is percentage.
Baseline,post-30 minutes, post-60 minutes, post-90 minutes, post-120 minutes, post-150 minutes, post-180 minutes, post-195 minutes (post-MLD), and post-225 minutes (30-minutes-post-MLD).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Heather Barnhart, PhD, Nova Southeastern University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 14, 2022

Primary Completion (Actual)

June 25, 2022

Study Completion (Actual)

June 25, 2022

Study Registration Dates

First Submitted

April 4, 2024

First Submitted That Met QC Criteria

May 3, 2024

First Posted (Actual)

May 8, 2024

Study Record Updates

Last Update Posted (Actual)

May 8, 2024

Last Update Submitted That Met QC Criteria

May 3, 2024

Last Verified

May 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

Undecided, plan to publish summary data in peer-reviewed journal

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Perfusion; Complications

Clinical Trials on Manual Lymphatic Drainage

Subscribe